Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Parasympathetic reactivation is essential for the rapid decrease in heart rate following exercise and delayed heart rate recovery (HRR) post-exercise is linked to poor clinical outcomes. Chronic kidney disease (CKD) is associated with autonomic dysfunction including reduced parasympathetic activity. Exercise training may improve parasympathetic reactivation. Therefore, this study aimed to test whether CKD patients experience delayed HRR due to impaired vagal reactivation and if 12 weeks of aerobic exercise can improve HRR.
Methods: Twenty-seven CKD patients (stages III and IV, eGFR 15-59 mL/min/1.73m2) and 18 age-matched controls underwent cardiopulmonary exercise testing (CPET). HRR was assessed through heart rate decay (HRR60s) and heart rate variability (HRV) during the first 60 seconds of recovery. Recovery kinetics were modeled to calculate the time constant (τ). CKD patients were then randomly assigned to aerobic exercise or non-aerobic stretching interventions for 12 weeks (3 days per week) and CPET was repeated post-intervention.
Results: CKD patients exhibited significantly blunted HRR60s (ΔHRR60s: -11 ± 4 bpm vs. -17 ± 6 bpm, P = 0.001) and a longer recovery time constant (τ: 142 ± 33 vs. 116 ± 21 s, P = 0.004) compared to controls. HRV indices increased less post-exercise in CKD patients compared to controls (ΔRMSSD: 0.3 ± 1 ms vs. 1.6 ± 1 ms, P = 0.001). 12 weeks of aerobic exercise did not improve HRR60s (ΔHRR60s: pre -12 ± 4 bpm vs. post -12 ± 7 bpm, P = 0.971) or HRV indices (all P > 0.108).
Conclusions: CKD patients have decreased HRR post-exercise due to impaired cardiac vagal reactivation. 12 weeks of aerobic exercise training did not improve cardiac vagal reactivation. Future studies should explore different exercise modalities and manipulate training variables such as intensity, volume and frequency to assess their potential impact on cardiac vagal reactivation in patients with CKD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1249/MSS.0000000000003824 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Copeptin in the diagnosis and management of renal tubular disorders.
Pediatr Nephrol
September 2025
Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).
View Article and Find Full Text PDFAdjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.
Cancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFOptimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.
Cureus
August 2025
Department of Cardiology, Apollo Hospitals, Indore, IND.
The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF).
View Article and Find Full Text PDFComparison of renal effects between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension and chronic kidney disease in Japan.
Clin Exp Nephrol
September 2025
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Background: Sacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior tolerability compared to thiazide diuretics. This post hoc study aimed to compare the effects of sacubitril/valsartan and thiazide diuretics in patients with chronic kidney disease (CKD).
View Article and Find Full Text PDFIntroduction: The residual risk of chronic kidney disease (CKD) progression remains high in clinical trials of kidney protective drugs in patients with diabetic kidney disease (DKD).
Methods: In a prospective study, we assessed whether 16 plasma and 10 urine cytokine levels can inform the residual risk of CKD progression in 93 incident patients with DKD treated by Nephrology according to clinical guidelines.
Results: Plasma and urine levels of 12 plasma and 7 urinary cytokines differed between patients with DKD and from healthy controls.